This paper discusses important new requirements for pre-market and post-market clinical investigations under the European MDR. It also addresses:
- the importance of defining the regulatory purpose of a study
- the relationship of a clinical investigation with quality management system (QMS) practices
- strategies for conducting a successful clinical investigation, including the importance of defining the steps for its planning and conduct